Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patients tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via subcutaneous injection. The formulations contain insulin, an oxidizing agent or enzyme and a reducing agent or enzyme, a diluent and optionally one or more thickening agents. If a thickening agent is present in the formulation, the thickening agent increases the viscosity of the formulation following administration. Preferably the formulation contains an insulin, a diluent, glucose oxidase and peroxidase. Following administration to a patient, the insulin is released from the formulations as a function of the patients tissue glucose level, which in turn maintains the patients blood glucose level within an optimum range. The formulation is often referred to as a "smart" formulation since it modifies its release rate of insulin according to the patients needs at a particular time. In a preferred embodiment, the formulation is designed to release insulin into the systemic circulation over time with a basal release profile following injection in a patient. In another embodiment, the formulation is designed to release insulin into the systemic circulation over time with a non-basal release profile following injection in a patient, such as a regular human insulin release profile or a prandial release profile.Linvention concerne des préparations dinsuline injectables qui peuvent modifier la quantité dinsuline libérée en fonction des taux de glucose dans les tissus dun patient, ainsi que des méthodes de production et dutilisation desdites préparations. La préparation peut être administrée par administration sous-cutanée, intradermique ou intramusculaire. Dans un mode de réalisation préféré, les préparations
